Mapping combinatorial drug effects to DNA damage response kinase inhibitors

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Cancer treatments often rely on inducing DNA damage to trigger apoptosis.
• The DNA Damage Response (DDR) pathway is crucial for cancer cell survival and therapeutic resistance.
• Targeting key DDR kinases (ATR, ATM, DNA-PK) presents a promising strategy for novel cancer therapies.

Purpose of the Study:

• To identify effective drug combinations targeting DDR kinases.
• To evaluate the combinatorial efficacy and synergy of various anti-cancer agents with DDR inhibitors.
• To analyze differential responses across diverse cancer types.

Main Methods:

• Conducted a comprehensive dose-response combination screening of 87 anti-cancer agents, including 6 DDR inhibitors.
• Tested combinations across 62 cancer cell lines representing 12 tumor types (17,912 experiments).
• Analyzed drug pair efficacy and synergy, considering tissue-specific variations.

Main Results:

• Identified potent synergistic drug combinations involving DDR inhibitors.
• Found that inhibitors of DNA topoisomerase, PLK1 kinase, p53-inducible ribonucleotide reductase, PARP, and cell cycle checkpoint proteins show strong synergy with ATM/ATR/DNA-PK inhibitors.
• Observed variations in combination efficacy across different cancer cell lines.

Conclusions:

• Combinations of specific DDR pathway inhibitors with ATM/ATR/DNA-PK inhibitors demonstrate significant anti-cancer potential.
• This approach offers a strategy for overcoming treatment resistance by exploiting cancer cell vulnerabilities in DNA repair.
• Further investigation into these synergistic combinations could lead to improved cancer treatment regimens.